Vertex Pharmaceuticals VRTX Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions?
- Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits increases resulting from current period tax positions of $29.88M in Q4 2025.
- How has Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions changed year-over-year?
- Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions increased by 0.3% year-over-year, from $29.8M to $29.88M.
- What is the long-term trend for Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions has grown at a 1.5% compound annual growth rate (CAGR), from $116M to $119.5M.